Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

7,880 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A phase 2 study of high-activity 186Re-HEDP with autologous peripheral blood stem cell transplant in progressive hormone-refractory prostate cancer metastatic to bone.
O'Sullivan JM, Norman AR, McCready VR, Flux G, Buffa FM, Johnson B, Coffey J, Cook G, Treleaven J, Horwich A, Huddart RA, Parker CC, Dearnaley DP. O'Sullivan JM, et al. Among authors: johnson b. Eur J Nucl Med Mol Imaging. 2006 Sep;33(9):1055-61. doi: 10.1007/s00259-005-0010-5. Epub 2006 Mar 30. Eur J Nucl Med Mol Imaging. 2006. PMID: 16572306 Clinical Trial.
Phase I/II trials of 186Re-HEDP in metastatic castration-resistant prostate cancer: post-hoc analysis of the impact of administered activity and dosimetry on survival.
Denis-Bacelar AM, Chittenden SJ, Dearnaley DP, Divoli A, O'Sullivan JM, McCready VR, Johnson B, Du Y, Flux GD. Denis-Bacelar AM, et al. Among authors: johnson b. Eur J Nucl Med Mol Imaging. 2017 Apr;44(4):620-629. doi: 10.1007/s00259-016-3543-x. Epub 2016 Oct 21. Eur J Nucl Med Mol Imaging. 2017. PMID: 27770145 Free PMC article.
Reply to 'Single high dose versus repeated bone-targeted radionuclide therapy'.
Denis-Bacelar AM, Chittenden SJ, Dearnaley DP, Divoli A, O'Sullivan JM, McCready VR, Johnson B, Du Y, Flux GD. Denis-Bacelar AM, et al. Among authors: johnson b. Eur J Nucl Med Mol Imaging. 2018 Mar;45(3):515-517. doi: 10.1007/s00259-017-3902-2. Eur J Nucl Med Mol Imaging. 2018. PMID: 29247283 No abstract available.
Phase I Trial of DNA Methyltransferase Inhibitor Guadecitabine Combined with Cisplatin and Gemcitabine for Solid Malignancies Including Urothelial Carcinoma (SPIRE).
Crabb SJ, Danson S, Catto JWF, Hussain S, Chan D, Dunkley D, Downs N, Marwood E, Day L, Saunders G, Light M, Whitehead A, Ellis D, Sarwar N, Enting D, Birtle A, Johnson B, Huddart R, Griffiths G. Crabb SJ, et al. Among authors: johnson b. Clin Cancer Res. 2021 Apr 1;27(7):1882-1892. doi: 10.1158/1078-0432.CCR-20-3946. Epub 2021 Jan 20. Clin Cancer Res. 2021. PMID: 33472913 Free PMC article. Clinical Trial.
7,880 results